Market Overview
The Asia Pacific cancer biomarkers market covers a broad spectrum of products and services, including blood-based assays, tissue biopsies, genomic and proteomic tests, and companion diagnostics used in oncology. Valued at roughly $11.35 billion in 2025, the market is forecast to grow at a CAGR of about 14.7% through the end of the decade, driven by both volume growth and rising test sophistication. The region is increasingly being viewed as a strategic growth frontier for global diagnostics players due to its large patient base and evolving regulatory frameworks.
- •2025 market size estimated at ~$11.35 billion with a ~14.7% CAGR outlook
- •Covers genomic, proteomic, and imaging-based biomarker technologies
- •Largest growth contribution expected from China, India, Japan, South Korea, and Australia
Growth Drivers
Rising cancer prevalence across Asia Pacific, particularly lung, breast, colorectal, and gastric cancers, is the primary demand-side driver for biomarker testing. Expanding reimbursement coverage, growing middle-class healthcare spending, and government-led screening programs are accelerating test adoption. At the same time, advances in next-generation sequencing (NGS), liquid biopsy, and AI-enabled diagnostic interpretation are improving clinical utility and lowering per-test costs.
- •Increasing cancer incidence and aging populations across emerging Asian economies
- •Faster regulatory approvals for companion diagnostics and NGS-based assays
- •Expansion of national screening programs in China, India, and Southeast Asia
Segmentation and Regional Analysis
By biomarker type, the market is segmented into genetic/genomic biomarkers (including DNA, RNA, and methylation-based markers), proteomic biomarkers, and imaging biomarkers, with genomic tests representing the fastest-growing category. By application, breast, lung, prostate, colorectal, and gastric cancers account for the majority of test volume, reflecting regional epidemiological patterns. Geographically, China and Japan lead in revenue contribution, while India and Southeast Asia are the highest-growth markets due to improving diagnostic infrastructure.
- •Genomic biomarkers are the fastest-growing segment, driven by NGS and liquid biopsy adoption
- •Breast, lung, and colorectal cancers represent the highest-volume applications
- •India and Southeast Asia projected to post above-regional-average growth rates
Trends and Outlook
What are the recent trends and outlook?
Key trends shaping the market through 2030 include the rise of liquid biopsy as a non-invasive alternative to tissue biopsy, deeper integration of multi-omics data (genomics, transcriptomics, proteomics) into clinical decision-making, and growing pharma-diagnostic partnerships for companion diagnostic development. AI and machine learning are being embedded into biomarker discovery and result interpretation workflows. Looking ahead, the market is expected to more than double in size by the early 2030s, with reimbursement expansion and decentralized testing models acting as the next major growth catalysts.
- •Liquid biopsy and ctDNA-based tests are gaining clinical traction for early detection and monitoring
- •Multi-omics integration and AI-driven interpretation are improving diagnostic accuracy
- •Decentralized and point-of-care biomarker testing is expected to expand access in tier-2 and tier-3 cities
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.